Loading...
Please wait, while we are loading the content...
Similar Documents
Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol
| Content Provider | SAGE Publishing |
|---|---|
| Author | Luo, Yonghong Peng, Daoquan |
| Copyright Year | 2023 |
| Abstract | Cardiovascular disease (CVD) caused by atherosclerosis is the leading cause of death worldwide. The level of low-density lipoprotein cholesterol (LDL-C), considered as the initiator of atherosclerosis, is the most widely used predictor for CVD risk and LDL-C has been the primary target for lipid-lowering therapies. However, residual CVD risk remains high even with very low levels of LDL-C. This residual CVD risk may be due to remnant cholesterol, high triglyceride levels, and low high-density lipoprotein cholesterol (HDL-C). Non-high density lipoprotein cholesterol (non-HDL-C), which is calculated as total cholesterol minus HDL-C (and represents the cholesterol content of all atherogenic apolipoprotein B-containing lipoproteins), has emerged as a better risk predictor for CVD than LDL-C and an alternative target for CVD risk reduction. Major international guidelines recommend evaluating non-HDL-C as part of atherosclerotic CVD risk assessment, especially in people with high triglycerides, diabetes, obesity, or very low LDL-C. A non-HDL-C target of <130 mg/dL (3.4 mmol/L) has been recommended for patients at very high risk, which is 30 mg/dL (0.8 mmol/L) higher than the corresponding LDL-C target goal. Non-HDL-C lowering approaches include reducing LDL-C and triglyceride levels, increasing HDL-C, or targeting multiple risk factors simultaneously. However, despite the growing evidence for the role of non-HDL-C in residual CVD risk, and recommendations for its assessment in major guidelines, non-HDL-C testing is not routinely done in clinical practice. Thus, there is a need for increased awareness of the need for non-HDL-C testing for ascertaining CVD risk and concomitant prevention of CVD. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/10742484231189597?download=true |
| ISSN | 10742484 |
| Volume Number | 28 |
| Journal | Journal of Cardiovascular Pharmacology and Therapeutics (CPT) |
| e-ISSN | 19404034 |
| DOI | 10.1177/10742484231189597 |
| Language | English |
| Publisher | Sage Publications CA |
| Publisher Date | 2023-08-28 |
| Publisher Place | Los Angeles |
| Access Restriction | Open |
| Rights Holder | © The Author(s) 2023 |
| Subject Keyword | lipid-lowering residual cardiovascular risk low-density lipoprotein cholesterol Xuezhikang non-high-density lipoprotein cholesterol |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology Pharmacology (medical) Cardiology and Cardiovascular Medicine |
